A Cardiologist’s Perspective on Cardiometabolic Risk - 15/08/11
Doi : 10.1016/j.amjcard.2007.10.008
Jorge Plutzky, MD ⁎ 
Vascular Disease Prevention Program, Cardiovascular Division, Brigham and Women’s Hospital, and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Address for reprints: Jorge Plutzky, MD, Brigham and Women’s Hospital, 77 Avenue Louis Pasteur, NRB 742, Boston, Massachusetts 02115.Résumé |
Many patients who present for cardiovascular evaluation meet the National Cholesterol Education Program (NCEP) criteria for the metabolic syndrome. Indeed, the metabolic abnormalities that characterize the syndrome are major drivers of atherosclerosis. Although definitive therapeutic interventions for the metabolic syndrome remain unclear, considerable data implicate adiposity as a core element of this constellation of abnormalities. Thus, for practicing cardiologists, the need to better understand and target adiposity is inescapable.
Le texte complet de cet article est disponible en PDF.Plan
| Statement of author disclosure: Please see the Author Disclosures section at the end of this article. |
© 2007
Elsevier Inc. Tous droits réservés.
Vol 100 - N° 12S1
P. S3-S6 - décembre 2007 Retour au numéro
Article précédent
- Introduction
- Carl J. Pepine, Jorge Plutzky
- The Endocannabinoid System in the Regulation of Cardiometabolic Risk Factors
- Luigi Bellocchio, Valentina Vicennati, Cristina Cervino, Renato Pasquali, Uberto Pagotto
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?